Literature DB >> 16242055

Esthesioneuroblastoma.

Heidi D Klepin1, Kevin P McMullen, Glenn J Lesser.   

Abstract

Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.

Entities:  

Mesh:

Year:  2005        PMID: 16242055     DOI: 10.1007/s11864-005-0029-7

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  26 in total

1.  Comparison of forward planned conformal radiation therapy and inverse planned intensity modulated radiation therapy for esthesioneuroblastoma.

Authors:  A Zabel; C Thilmann; I Zuna; W Schlegel; M Wannenmacher; J Debus
Journal:  Br J Radiol       Date:  2002-04       Impact factor: 3.039

2.  Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma.

Authors:  Yuko Mishima; Eijiro Nagasaki; Yasuhito Terui; Tetsuya Irie; Shunji Takahashi; Yoshinori Ito; Masahiko Oguchi; Kazuyoshi Kawabata; Shinetsu Kamata; Kiyohiko Hatake
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

Review 3.  Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience.

Authors:  Rod J Oskouian; John A Jane; Aaron S Dumont; Jonas M Sheehan; Jeffrey J Laurent; Paul A Levine
Journal:  Neurosurg Focus       Date:  2002-05-15       Impact factor: 4.047

4.  Esthesioneuroblastoma. Long-term outcome and patterns of failure--the University of Virginia experience.

Authors:  B V Eden; R F Debo; J M Larner; M D Kelly; P A Levine; F M Stewart; R W Cantrell; W C Constable
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

5.  The minimally invasive approach to olfactory neuroblastoma: combined endoscopic and stereotactic treatment.

Authors:  C Walch; H Stammberger; W Anderhuber; F Unger; W Köle; K Feichtinger
Journal:  Laryngoscope       Date:  2000-04       Impact factor: 3.325

6.  Olfactory neuroblastoma: past, present, and future?

Authors:  Valerie J Lund; David Howard; William Wei; Margaret Spittle
Journal:  Laryngoscope       Date:  2003-03       Impact factor: 3.325

7.  Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.

Authors:  Dong-Wan Kim; Yo-Han Jo; Jee Hyun Kim; Hong-Gyun Wu; Chae Seo Rhee; Chol Hee Lee; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

8.  Treatment of intracranial metastatic esthesioneuroblastoma.

Authors:  Marc C Chamberlain
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

9.  Esthesioneuroblastoma: irradiation alone and surgery alone are not enough.

Authors:  Günther Gruber; Kurt Laedrach; Brigitta Baumert; Marco Caversaccio; Joram Raveh; Richard Greiner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

10.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

View more
  7 in total

1.  Esthesioneuroblastoma metastatic to the trachea.

Authors:  F Mattavelli; N Pizzi; E Pennacchioli; S Radaelli; G Calarco; P Quattrone; L Patelli; P Spinelli
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-06       Impact factor: 2.124

2.  Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes.

Authors:  Diana Bell; Rami Saade; Dianna Roberts; Thomas J Ow; Michael Kupferman; Franco DeMonte; Ehab Y Hanna
Journal:  Head Neck Pathol       Date:  2014-05-08

Review 3.  Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment.

Authors:  Shirley Y Su; Diana Bell; Ehab Y Hanna
Journal:  Int Arch Otorhinolaryngol       Date:  2014-10

4.  Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment.

Authors:  Walavan Sivakumar; Nathan Oh; Aaron Cutler; Howard Colman; William T Couldwell
Journal:  Surg Neurol Int       Date:  2015-11-25

5.  Esthesioneuroblastoma located in the thoracic extradural space: Case report.

Authors:  Mehmet Hüseyin Akgul; Ferruh Gezen; Ali Kemal Uzunlar
Journal:  Int J Surg Case Rep       Date:  2016-07-30

6.  Heavily Calcified Esthesioneuroblastoma in a 72-year-old.

Authors:  Robert Maurer; April Henry; Timothy Maurer; Ghazal Staity; Nicole Williams; Neerav Goyal; Brad Zacharia
Journal:  Cureus       Date:  2019-03-22

7.  Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature.

Authors:  Domenico Cante; Cristina Piva; Piera Sciacero; Pierfrancesco Franco; Edoardo Petrucci; Valeria Casanova Borca; Fabrizio Marola; Libero Tubino; Giorgio Vellani; Maria Rosa La Porta
Journal:  BJR Case Rep       Date:  2018-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.